Capricor Q1 net loss $24.4M; deramiocel BLA PDUFA Aug 31, 2025

CAPRICOR THERAPEUTICS, INC.

2025-Q1 EPS reported -$0.53

Net loss of $24.4M ($0.53/sh) vs $9.8M loss ($0.31/sh) in Q1 2024; revenue $0 vs $4.9M.
Cash and equivalents $144.8M as of Mar 31, 2025; expected to fund operations into 2027.
FDA accepted BLA for deramiocel in DMD-cardiomyopathy with priority review; PDUFA date Aug 31, 2025.
Mid-cycle review with FDA completed; no significant deficiencies identified; advisory committee planned.
Appointed Dr. Michael Binks as CMO; NIAID plans to initiate StealthX vaccine Phase 1 trial in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.